Navigation Links
NeurogesX Reports First Quarter 2011 Results
Date:4/29/2011

concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza for the management of pain due to HIV-associated neuropathy (HIV-AN) also known as HIV-distal sensory polyneuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient dosing is underway in a Phase 2 clinical trial in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated certain of these compounds in vitro and in vivo.

Safe Harbor Statement This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in th
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
2. NeurogesX Reports Fourth Quarter and Year-End 2010 Results
3. NeurogesX to Provide Qutenza® Launch Update
4. NeurogesX to Present at Two February Investor Conferences
5. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
6. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
7. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
8. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
9. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
10. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
11. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... OAKS, Calif., April 13, 2011 Amgen (NASDAQ: ... first quarter financial results on Wednesday, April 20, 2011 after ... be followed by a conference call with the investment community ... Amgen will be Kevin Sharer, chairman and chief executive officer, ...
... 13, 2011 Perrigo (Nasdaq: PRGO;TASE) today announced that ... TEVA ), has received final OTC approval to sell ... tablets; the generic equivalents of Sanofi-Aventis, Allegra 60 mg ... for these products, and Teva and Sanofi-Aventis have settled ...
Cached Medicine Technology:Amgen Announces Webcast of 2011 First Quarter Financial Results 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 3
(Date:7/9/2014)... has risen dramatically in Western societies. One frequently cited ... and have fewer infections than previous generations, thereby delaying ... researchers at Sahlgrenska Academy, University of Gothenburg, monitored children ... the immune system in relation to allergic disease. All ... Vstra Gtaland Region, half of them on farms that ...
(Date:7/8/2014)... Restoration has been awarded up to $15 million by ... four -year project aiming to help brain-injured people restore ... neurosurgery, engineering, neurobiology, psychology and physics will collaborate to ... the brain. , Memory is the process in which ... store it and retrieve it. Certain types of illnesses ...
(Date:7/8/2014)... hygiene rates were found to be three times higher ... there were no auditors present, according to a study ... The study, titled, "Quantification of the Hawthorne effect in ... a retrospective cohort study," published today on-line in the ... author Dr. Jocelyn Srigley, who did the study as ...
(Date:7/8/2014)... have increased risks of dying at a young age ... stroke, diabetes, and kidney and liver diseases, according to ... large studies of people from three countries. The study, ... part of the National Institutes of Health, found that ... dramatic reduction in life expectancy compared with people of ...
(Date:7/8/2014)... Military physicians will soon pick up joysticks instead of ... with serious health threats. , James Gerard, M.D., a professor ... grant from the Department of Defense Office of Naval ... a video game that will train physicians on pediatric emergency ... use one of the most popular tools gaming ...
Breaking Medicine News(10 mins):Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3Health News:NCI study finds extreme obesity may shorten life expectancy up to 14 years 2Health News:Save, don't kill: SLU pediatrician to develop educational video game for training military physician 2
... Announce the Houston Tackles Autism Campaign, HOUSTON, ... running back Ahman Green, representatives from Reliant Energy, ... are holding a,news conference to raise awareness about ... book Playing Together: Tips from the Pros. ...
... Also Renews Commitment to Darfur, STAMFORD, Conn., Oct. ... more than $7,billion in aid to people in need ... AmeriCares President and CEO Curt Welling announced the milestone ... held at Westchester County Airport on Saturday., "I ...
... with their doctors , , MONDAY, Oct. 15 (HealthDay News) ... implantable defibrillators -- voluntarily stopped distribution of Sprint Fidelis ... wires could fracture, potentially triggering cardiac events. , The ... implanted defibrillators wondering what to do next. , But ...
... 15 Today, Easter Seals awarded members,of state ... Easter Seals annual convention currently being held in ... to honor public,officials -- elected and appointed -- ... for people with disabilities, and for all. ...
... ,Family,Matters, Study, BOSTON, Oct. 15 It could be ... look as if they,re,turning away from their family in favor ... A lot., A study led by Simmons School of ... importance to adolescents that they feel,valued by their family, and ...
... Calif., Oct. 15 Digirad Corporation,(Nasdaq: DRAD ... systems,and services to physicians, offices, hospitals and imaging ... Deloitte,s Technology Fast 50 Program,for San Diego. The ... and life sciences companies in the,San Diego area ...
Cached Medicine News:Health News:Reliant Energy, Houston Texans' Ahman Green and Matt Schaub Team to Hold News Conference, Book Signing to Raise Awareness about Autism 2Health News:Reliant Energy, Houston Texans' Ahman Green and Matt Schaub Team to Hold News Conference, Book Signing to Raise Awareness about Autism 3Health News:AmeriCares Passes $7 Billion Mark in Aid Distributed 2Health News:Defib Wire Warning Shouldn't Worry Most Users: Experts 2Health News:Defib Wire Warning Shouldn't Worry Most Users: Experts 3Health News:Defib Wire Warning Shouldn't Worry Most Users: Experts 4Health News:Easter Seals Awards State and Municipal Public Officials With 2007 Outstanding Advocate Awards 2Health News:A Best-Kept Secret of Your Teen: They Really Do Care What You Think, Simmons College Study Shows 2Health News:Digirad Corporation Named to Deloitte Technology Fast 50 2Health News:Digirad Corporation Named to Deloitte Technology Fast 50 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: